Compare abrdn Income Credit Strategies Fund (ACP) vs Dolby Laboratories, Inc. (DLB) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
abrdn Income Credit Strategies Fund vs Dolby Laboratories, Inc. — how do they compare? abrdn Income Credit Strategies Fund trades at $5.21 (market cap $656.21M), while Dolby Laboratories, Inc. trades at $50.25 (market cap $4.66B). The key difference: Dolby Laboratories, Inc. is far larger — about 7.1× abrdn Income Credit Strategies Fund's market cap, and abrdn Income Credit Strategies Fund pays the higher dividend (17.78%). Which is the better fit depends on your goals.
| ACP | DLB | |
|---|---|---|
Market Cap | $656.21M | $4.66B |
Sector | Financials | Industrials |
52-Week High | $5.98 | $76.79 |
52-Week Low | $5.01 | $49.31 |
Dividend Yield | 17.78% | 2.86% |
Enterprise Value | — | $4.12B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACP trades at $5.25, down 0.57% today, with a neutral technical signal. The stock shows a low P/B of 0.89 and a high net income margin of 95.51% for 2024, though revenue declined from $79M in 2024 to $42M in 2025. Recent news highlights dividend declarations and a Seeking Alpha downgrade citing distribution sustainability concerns. Cash flow from operations was negative $81.31M in 2024, offset by financing inflows.
Outlook is mixed: valuation appears modest with a P/E near 16, but declining revenue and negative operating cash flow pose risks. The 17% distribution rate faces sustainability questions, while technical indicators suggest limited near-term momentum. Investors should weigh income potential against fundamental weaknesses and high beta exposure.
DLB trades at $49.31, down 3.6% today, with technical indicators showing bearish momentum. The company maintains strong fundamentals with consistent earnings beats, including Q1 2026 EPS of $1.37 versus $1.31 expected. Revenue remains stable at $1.35B for 2025, with robust gross margins of 87.44%. Recent developments include FDA progress for zervimesine in DLB psychosis and recognition as GM's 2025 Supplier of the Year.
Despite near-term technical weakness, DLB's patent-protected revenue streams and high profitability support long-term value. The consensus price target of $87.50 implies significant upside, but investors face risks from cyclical end-markets and potential dilution from drug development. The stock presents a contrarian opportunity with 47% analyst buy ratings amid current bearish sentiment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About abrdn Income Credit Strategies Fund
abrdn Income Credit Strategies Fund is a diversified, closed-end investment management company. Its primary goal is to generate high current income, with capital appreciation as a secondary objective. The fund mainly invests in debt and loan instruments from issuers across various industries and regions.
Read more on ACP →About Dolby Laboratories, Inc.
Dolby Laboratories Inc develops audio and surround sound for cinema, broadcast, home audio systems, in-car entertainment systems, DVD players, games, televisions, and personal computers. The company generates three fourths of its revenue from licensing its technology to consumer electronics manufacturers around the world. The rest of revenue comes from equipment sales to professional producers and audio engineering services.
Read more on DLB →
